

## REMARKS

### Rejection of the Claims Under 35 U.S.C. §112, Second Paragraph

Claims 8 and 17 have been rewritten to incorporate SEQ ID NO:87 for the Ph1 p 5b polypeptide. Claims 9 and 19 have been rewritten according to the Examiner's preferred alternative of conventional Markush language.


Claims 20 and 21 have been rewritten, at the suggestion of the Examiner, to replace "modified" with said modification. The rejection of the claims under 112, second paragraph is now moot and should be withdrawn.


Applicants reserve the right to recapture any non-elected subject matter in subsequently filed divisional or continuation applications.

In view of the above remarks and amendments, favorable consideration of the application is courteously requested. However, if there is any remaining issue(s) which can be expeditiously resolved by a telephone conference, the Examiner is courteously requested to telephone the undersigned at the number indicated below.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,

  
Robert E. McCarthy (Reg. No. 46.044)  
Representative Capacity

  
Anthony J. Zelano (Reg. No. 27.969)  
Attorney for Applicants  
*MILLEN, WHITE, ZELANO & BRANIGAN, P.C.*  
Arlington Courthouse Plaza I, Suite 1400  
2200 Clarendon Boulevard  
Arlington, Virginia 22201  
Direct Dial: (703) 812-5322  
Email: [mccarthy@mwzb.com](mailto:mccarthy@mwzb.com)

**Filed: April 14, 2003**

K: Merck:2034/reply to OA 1-13-03 word